Financial PerformanceManagement expects large pharma will continue to rely on TechBio companies such as Recursion despite recent efforts to build out internal AI/ML capabilities, and views RXRX as the only Public name of sufficient heft.
Operational EfficiencyRecent cost-cutting measures are expected to lower operational expenses by approximately 35%, which is likely to improve financial efficiency.
PartnershipsRecursion achieved a $7mm discovery milestone under the Sanofi collaboration for lead series development of an immunology target.